Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Moleculin Biotech Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
MBRX
Nasdaq
2834
https://moleculin.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Moleculin Biotech Inc
Moleculin Biotech (NASDAQ:MBRX) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team
- Apr 25th, 2024 1:45 pm
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
- Apr 18th, 2024 12:30 pm
Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties
- Apr 10th, 2024 12:30 pm
Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference
- Mar 28th, 2024 2:45 pm
Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity
- Mar 27th, 2024 1:25 pm
Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML
- Mar 27th, 2024 1:05 pm
Moleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2023 Earnings Call Transcript
- Mar 26th, 2024 12:36 pm
Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
- Mar 25th, 2024 11:30 am
Moleculin Biotech Inc Reports Fiscal Year 2023 Financial Results
- Mar 22nd, 2024 9:31 pm
Moleculin Reports Full Year 2023 Financial Results
- Mar 22nd, 2024 8:05 pm
Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast
- Mar 20th, 2024 11:30 am
Moleculin Announces Reverse Stock Split
- Mar 19th, 2024 8:30 pm
Moleculin to Present at the 36th Annual ROTH Conference
- Mar 12th, 2024 1:05 pm
Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3
- Jan 24th, 2024 1:50 pm
Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
- Dec 21st, 2023 2:16 am
Here's Why We're A Bit Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation
- Dec 20th, 2023 11:47 am
Moleculin Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML at Meeting with KOL's in Conjunction with ASH Annual Meeting
- Dec 11th, 2023 1:50 pm
Moleculin Biotech, Inc. (NASDAQ:MBRX) Q3 2023 Earnings Call Transcript
- Nov 14th, 2023 6:46 pm
Moleculin (MBRX) Up 7% on Upbeat Updates From Annamycin Studies
- Nov 14th, 2023 3:29 pm
Moleculin Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months
- Nov 13th, 2023 1:05 pm
Scroll